Stock IVVD INVIVYD, INC.
Add to a list

Invivyd, Inc. Stock

Stocks

IVVD

US00534A1025

Pharmaceuticals

Market Closed -
Nasdaq
16:00:00 2026-11-06 EST 		5-day change 1st Jan Change
0.5630 USD -3.76% Intraday chart for Invivyd, Inc. -3.21% -77.21%
10-21 Invivyd, Inc. Presents VMS063, A Potential Best-In-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, At IDWeek 2026 CI
10-14 Invivyd, Inc. and The SPEAR Study Group Announce Initiation Of FLINTLOCK Phase 2 Study Of VYD2311, A Monoclonal Antibody For The Potential Treatment Of Long COVID Or Post-Vaccination Syndrome CI

Valuation: Invivyd, Inc.

Market Cap 166M 149M 136M 124M 234M 15.6B 241M 1.64B 654M 8.32B 623M 610M 26.28B P/E 2026 *
-1.07x
P/E 2027 * -1.72x
Enterprise Value 166M 149M 136M 124M 234M 15.6B 241M 1.64B 654M 8.32B 623M 610M 26.28B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 1.91x
Free-Float
92.84%
Yield 2026 *
-
Yield 2027 * -
* Estimated data More valuation ratios

Chart: Invivyd, Inc.

NasdaqUSD
MarketsQuality
Nasdaq
IVVD Delayed
CBOE
IVVD Real-time
Dynamic Chart

Latest news: Invivyd, Inc.

10-21 Invivyd, Inc. Presents VMS063, A Potential Best-In-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, At IDWeek 2026 CI
10-14 Invivyd, Inc. and The SPEAR Study Group Announce Initiation Of FLINTLOCK Phase 2 Study Of VYD2311, A Monoclonal Antibody For The Potential Treatment Of Long COVID Or Post-Vaccination Syndrome CI
09-29 Invivyd, Inc. - Special Call
09-29 Invivyd's VYD2311 Meets Primary Goals in Head-to-Head mRNA Vaccine Trial MT
09-29 Invivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to Mrna-Based Covid-19 Vaccine and Announces Regulatory Submission Plans for VYD2311 CI
09-29 Invivyd, Inc. Announces Positive Topline Results from Liberty Phase 3 Study Demonstrating Vyd2311 Safety and Tolerability Superior to Mrna-Based Covid-19 Vaccine CI
09-20 Invivyd, Inc.(NasdaqGM:IVVD) added to S&P Global BMI Index CI
09-01 Invivyd, Inc. Announces Appointment of Marc W. Elia to Chief Executive Officer, Effective August 30, 2026 CI
09-01 Invivyd, Inc. Announces Board Changes, Effective August 30, 2026 CI
09-01 Invivyd, Inc. Announces Results of VYD2311 Studies DECLARATION And LIBERTY CI
09-01 Invivyd Names Chairman Marc Elia as CEO MT
08-13 Invivyd, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-06 Healthcare Stocks Decline as Investors Rotate Away from Safety -- Healthcare Roundup DJ
More news

Last Transcript: Invivyd, Inc.

Logo Invivyd, Inc.
Invivyd, Inc. - Special Call
09-29
More transcripts

Analysts' recommendations: Invivyd, Inc.

12-22 BTIG Initiates Invivyd at Buy With $10 Price Target MT
25-10-19 Certain Options of Invivyd, Inc. are subject to a Lock-Up Agreement Ending on 20-OCT-2025. CI
25-10-06 Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target MT
25-10-06 Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug DJ
24-04-05 Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9 MT
More recommendations

Press Releases: Invivyd, Inc.

11-03 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GL
10-21 Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026 GL
10-14 Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome GL
10-06 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) AQ
10-05 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GL
More press releases

News in other languages: Invivyd, Inc.

22-03-31 Adagio Therapeutics annonce que l'ADG20 (adintrevimab) est le premier anticorps monoclonal à répondre aux critères d'évaluation primaires ayant une importance statistique dans l'ensemble de la prophylaxie pré et post-exposition et du traitement pour la COVID-19, et prévoit de demander une autorisation d'utilisation d'urgence aux États-Unis
22-03-31 Adagio Therapeutics anuncia que ADG20 (adintrevimab) es el primer anticuerpo monoclonal que cumple con los principales criterios de valoración con importancia estadística en la profilaxis pre-exposición (PrEP) y profilaxis post-exposición (PEP).y tratamiento de COVID-19 y planea solicitar autorización de uso de emergencia en Estados Unidos
22-03-31 Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mit statistischer Signifikanz erreicht hat, und plant die Beantragung der Notfallzulassung in den USA
22-01-13 Adagio Therapeutics resume actividad neutralizante de ADG20 contra variantes de SARS-CoV-2 y describe iniciativas para abordar la variante ómicron
22-01-13 Adagio Therapeutics legt zusammenfassende Ergebnisse zur neutralisierenden Wirkung von ADG20 gegenüber SARS-CoV-2-Varianten vor und stellt Initiativen zur Bekämpfung von Omikron vor
More news

Quotes and Performance

1 day-3.76%
1 week-3.21%
Current month-3.21%
1 month-30.18%
3 months-14.57%
6 months-61.44%
Current year-77.21%
More quotes

Price Extremes

1 week 0.55
Extreme 0.55
 0.64
1 month 0.54
Extreme 0.5375
 0.74
Current year 0.53
Extreme 0.5277
 2.78
1 year 0.53
Extreme 0.5277
 3.07
3 years 0.35
Extreme 0.3546
 5.2
5 years 0.35
Extreme 0.3546
 78.82
10 years 0.35
Extreme 0.3546
 78.82
More quotes

Managers and Directors: Invivyd, Inc.

Manager TitleAgeSince
Marc Elia CEO
 Chief Executive Officer 50 2026-08-29
William Duke CEO
 Chief Executive Officer 53 2024-05-29
Michael Mina CTO
 Chief Tech/Sci/R&D Officer 42 2026-03-04
Director TitleAgeSince
Terry McGuire BRD
 Director/Board Member 70 2020-09-30
Ajay Royan BRD
 Director/Board Member 46 2025-03-25
Tamsin Berry BRD
 Director/Board Member 45 2022-06-21
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26
Ian Sheffield
Free

Director

100,000 0.0339%
8/30/26
Marc Elia
Free

Chief Executive Officer

10,700,000 3.6301%
8/18/26
Timothy Lee
Sell

Executive/Senior Manager

-18,425 0.0063%
Transaction History

Other Pharmaceuticals

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
INVIVYD, INC. Stock Invivyd, Inc.
-3.76%-3.21%-63.44%-62.72% 172M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
-0.79%-4.48%+44.44%+127.49% 1,216B
JOHNSON & JOHNSON Stock Johnson & Johnson
+1.43%+1.11%+47.73%+82.08% 656B
ABBVIE INC. Stock AbbVie Inc.
+1.07%-1.21%+32.99%+106.31% 509B
ROCHE HOLDING AG Stock Roche Holding AG
-0.36%-3.25%+47.17%+64.58% 384B
MERCK & CO., INC. Stock Merck & Co., Inc.
-0.14%-1.87%+71.05%+40.63% 362B
NOVARTIS AG Stock Novartis AG
-0.78%-0.52%+30.57%+57.98% 311B
ASTRAZENECA PLC Stock AstraZeneca PLC
-0.80%-0.21%+8.54%+35.56% 293B
AMGEN INC. Stock Amgen Inc.
+0.03%-1.20%+45.89%+68.76% 249B
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-0.41%-2.22%+35.24%+105.68% 208B
Average -0.45%-0.62%+30.02%+62.63% 418.8B
Weighted average by Cap. -0.05%-1.21%+42.20%+88.35%
See all sector performances

Financials

2026 *2027 *
Net sales 60.05M 53.86M 49.22M 44.93M 84.66M 5.65B 87.33M 593M 237M 3.01B 225M 221M 9.51B 86.98M 78.02M 71.3M 65.09M 123M 8.18B 126M 859M 343M 4.36B 326M 319M 13.77B
Net income -169M -152M -139M -127M -239M -15.93B -246M -1.67B -667M -8.5B -636M -622M -26.83B -112M -101M -91.91M -83.9M -158M -10.54B -163M -1.11B -442M -5.62B -421M -412M -17.75B
Net Debt - -
Projected Income Statement - Annual - Invivyd, Inc.
* Estimated data More financial data

Company Profile

Logo Invivyd, Inc.
Invivyd, Inc. is a biopharmaceutical company. The Company’s proprietary INVYMAB platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to keep pace with evolving viral threats. The Company delivers antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, such as SARS-CoV-2. Its PEMGARDA (pemivibart) is the Company's first mAb to receive regulatory authorization and is designed to keep pace with SARS-CoV-2 viral evolution. PEMGARDA is used for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents. Its VYD2311 is optimized for neutralization potency against SARS-CoV-2 lineages such as BA.2.86 and JN.1. The Company also has additional anti-SARS-CoV-2 mAb candidates in discovery and pre-clinical characterization.
Employees
122
Sector
Pharmaceuticals
More about the company

Quotes

Date Price Change Volume
26-11-06 US$0.5630 -3.76% 2,335,832
26-11-05 US$0.5850 -7.67% 4,562,221
26-11-04 US$0.6336 +8.96% 4,547,626
26-11-03 US$0.5815 -0.09% 9,319,450
26-11-02 US$0.5820 +0.05% 4,431,241

Delayed Quote Nasdaq

More quotes

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

-
Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.

-
Quality

Quality

This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.

-
ESG MSCI

ESG MSCI

The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

-
MarketScreener Ratings - Invivyd, Inc.
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.5630USD
Average target price
10.00USD
Spread / Average Target
+1,676.20%
Consensus
EPS Estimates
Evolution of Analysts' Estimates - EPS - Invivyd, Inc.
Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Invivyd, Inc.
Company calendar
  1. Stock Market
  2. Stocks
  3. IVVD Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong